Research programme: CD22 targeted CAR T cell therapies - Sana Biotechnology
Latest Information Update: 19 Jan 2022
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research B-cell lymphoma
Most Recent Events
- 11 Jan 2022 Sana Biotechnology licenses worldwide exclusive commercial rights to the National Institute of Health's CD22 chimeric antigen receptor (CAR) with a fully-human binder for development of in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies
- 11 Jan 2022 Early research in B-cell lymphoma in USA (Parenteral)